These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24063613)

  • 21. Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.
    Duan H; Kachko A; Zhong L; Struble E; Pandey S; Yan H; Harman C; Virata-Theimer ML; Deng L; Zhao Z; Major M; Feinstone S; Zhang P
    J Virol; 2012 Dec; 86(23):12686-94. PubMed ID: 22973024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins.
    Liu R; Rao H; Wang J; Xie X; Jiang D; Pan X; Zhao P; Zhang H; Wei L
    PLoS One; 2013; 8(6):e66872. PubMed ID: 23826163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
    Eren R; Landstein D; Terkieltaub D; Nussbaum O; Zauberman A; Ben-Porath J; Gopher J; Buchnick R; Kovjazin R; Rosenthal-Galili Z; Aviel S; Ilan E; Shoshany Y; Neville L; Waisman T; Ben-Moshe O; Kischitsky A; Foung SK; Keck ZY; Pappo O; Eid A; Jurim O; Zamir G; Galun E; Dagan S
    J Virol; 2006 Mar; 80(6):2654-64. PubMed ID: 16501075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of epitopes for neutralizing monoclonal antibodies to classical swine fever virus E2 and Erns using phage-displayed random peptide library.
    Zhang F; Yu M; Weiland E; Morrissy C; Zhang N; Westbury H; Wang LF
    Arch Virol; 2006 Jan; 151(1):37-54. PubMed ID: 16132176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
    Schofield DJ; Bartosch B; Shimizu YK; Allander T; Alter HJ; Emerson SU; Cosset FL; Purcell RH
    Hepatology; 2005 Nov; 42(5):1055-62. PubMed ID: 16250048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
    Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
    J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Prentoe J; Velázquez-Moctezuma R; Foung SK; Law M; Bukh J
    Hepatology; 2016 Dec; 64(6):1881-1892. PubMed ID: 27351277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological properties of purified recombinant HCV particles with an epitope-tagged envelope.
    Takahashi H; Akazawa D; Kato T; Date T; Shirakura M; Nakamura N; Mochizuki H; Tanaka-Kaneko K; Sata T; Tanaka Y; Mizokami M; Suzuki T; Wakita T
    Biochem Biophys Res Commun; 2010 May; 395(4):565-71. PubMed ID: 20399750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus.
    Abdel Malak CA; Abelhafez TH; Tabll AA; Mashaly MM; El Shenawy R; El-Abd YS; Shaker MH; El-Awady MK
    Hum Antibodies; 2017; 26(3):127-134. PubMed ID: 29036810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits.
    Shang D; Zhai W; Allain JP
    Virology; 1999 Jun; 258(2):396-405. PubMed ID: 10366577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape.
    Krey T; Meola A; Keck ZY; Damier-Piolle L; Foung SK; Rey FA
    PLoS Pathog; 2013; 9(5):e1003364. PubMed ID: 23696737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
    Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
    Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
    Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
    Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.
    Pedersen J; Carlsen TH; Prentoe J; Ramirez S; Jensen TB; Forns X; Alter H; Foung SK; Law M; Gottwein J; Weis N; Bukh J
    Hepatology; 2013 Nov; 58(5):1587-97. PubMed ID: 23729237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Infect Dis; 2019 Jan; 219(1):68-79. PubMed ID: 30102355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.
    Sautto G; Tarr AW; Mancini N; Clementi M
    Clin Dev Immunol; 2013; 2013():450963. PubMed ID: 23935648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization.
    Deng L; Hernandez N; Zhong L; Holcomb DD; Yan H; Virata ML; Tarafdar S; Xu Y; He Y; Struble E; Alter HJ; Zhang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34260404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2.
    Angus AG; Patel AH
    Future Microbiol; 2011 Mar; 6(3):279-94. PubMed ID: 21449840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.